Celularity Inc
For the period ended Mar 31, 2024. Filed Oct 16, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed Oct 16, 2024
CELU$0.76-0.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except share and per share amounts)
| March 31,2024 | December 31,2023 | |
|---|---|---|
| (unaudited) | ||
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $1,902 | $227 |
| Accounts receivable, net of allowance of $6,038 and $5,837 as of March 31,2024 and December 31, 2023, respectively | 13,769 | 10,046 |
| Notes receivable | 2,072 | 2,072 |
| Inventory | 3,701 | 5,753 |
| Prepaid expenses and other current assets | 1,411 | 1,695 |
| Total current assets | 22,855 | 19,793 |
| Property and equipment, net | 66,268 | 67,828 |
| Goodwill | 7,347 | 7,347 |
| Intangible assets, net | 10,455 | 11,001 |
| Right-of-use assets - operating leases | 10,945 | 10,990 |
| Restricted cash | 10,046 | 9,936 |
| Inventory, net of current portion | 15,573 | 16,657 |
| Other long-term assets | 327 | 337 |
| Total assets | $143,816 | $143,889 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $12,983 | $14,144 |
| Accrued expenses and other current liabilities | 8,755 | 7,580 |
| Accrued R&D software | 1,700 | 3,500 |
| Short-term debt - unaffiliated (includes debt measured at fair value of $2,183 at March 31, 2024 and $17,223 at December 31, 2023, respectively) | 5,101 | 19,331 |
| Short-term debt - related parties | 34,699 | 19,909 |
| Deferred revenue | 2,806 | 2,834 |
| Total current liabilities | 66,044 | 67,298 |
| Deferred revenue, net of current portion | 3,265 | 3,186 |
| Acquisition-related contingent consideration | 1,606 | 1,606 |
| Noncurrent lease liabilities - operating | 26,265 | 26,177 |
| Warrant liabilities | 15,092 | 4,359 |
| Deferred income tax liabilities | 9 | 9 |
| Other liabilities | 290 | 294 |
| Total liabilities | 112,571 | 102,929 |
| Commitments and contingencies (Note 9) | ||
| Stockholders’ equity | ||
| Preferred stock, $0.0001 par value, 10,000,000 shares authorized, none issued and outstandingat March 31, 2024 and December 31, 2023 | - | - |
| Common Stock, $0.0001 par value, 730,000,000 shares authorized, 21,808,752 issued and outstanding as of March 31, 2024; 730,000,000 shares authorized, 19,378,192 issued and outstanding as of December 31, 2023 | 2 | 2 |
| Additional paid-in capital | 895,047 | 882,749 |
| Accumulated deficit | (863,804) | (841,791) |
| Total stockholders’ equity | 31,245 | 40,960 |
| Total liabilities and stockholders’ equity | $143,816 | $143,889 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.